140 Participants Needed
Massachusetts General Hospital logo

Vagus Nerve Stimulation for Alzheimer's Disease

(WALLe Trial)

HI
NE
NE
Overseen ByNina Engels, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Massachusetts General Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial requires that your medications be stable for at least 30 days before participating, so you may need to continue your current medications without changes.

What data supports the effectiveness of the treatment Vagus Nerve Stimulation for Alzheimer's Disease?

Transcutaneous vagus nerve stimulation (tVNS) has been shown to modulate brain activity and has been used successfully for conditions like epilepsy and depression, suggesting potential benefits for Alzheimer's Disease. It is a non-invasive method that stimulates the vagus nerve through the skin, which may help in managing symptoms by affecting brain function.12345

Is transcutaneous auricular vagus nerve stimulation (taVNS) safe for humans?

Transcutaneous auricular vagus nerve stimulation (taVNS) is generally considered safe, with mild and temporary side effects like ear pain, headache, and tingling. Studies show no significant risk of severe adverse events, making it a feasible option for clinical use.25678

How does the treatment of transcutaneous vagus nerve stimulation for Alzheimer's disease differ from other treatments?

This treatment is unique because it uses non-invasive electrical stimulation of the ear to activate the vagus nerve, which may enhance cognitive function without the need for surgery or medication. Unlike traditional treatments, it offers a novel approach by potentially improving brain function through the modulation of neural pathways and cardiovascular stability.910111213

What is the purpose of this trial?

In this research study the investigators want to find out if a non-invasive electrical brain stimulation method called RAVANS (also called tVNS) can have a beneficial effect on cognition in older individuals. The investigators also want to understand whether certain individual factors contribute to the effect of RAVANS on cognition. RAVANS is only used in research studies.

Research Team

HI

Heidi IL Jacobs, PhD

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

This trial is for individuals aged 60-85 with mild Alzheimer's or aging-related cognitive decline, fluent in English, and have stable health conditions like controlled hypertension. They must score within certain limits on cognitive tests and be right-handed. Exclusions include metal implants incompatible with MRI, severe psychiatric disorders, active cancer or heart disease, major head trauma history, substance abuse within the past two years.

Inclusion Criteria

Fluent in English
Right-handed
Willingness and ability to comply with scheduled visits, magnetic resonance imaging (MRI) scanning, laboratory tests, and other study procedures
See 7 more

Exclusion Criteria

I have an active blood, kidney, lung, hormone, or liver disorder.
I have a serious heart condition or have had a stroke.
Substance abuse within the past 2 years
See 16 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Cross-over Intervention

Participants undergo a cross-over design of sham versus RAVANS stimulation during a functional magnetic resonance imaging (fMRI) task

4 weeks
2 sessions

Treatment

Participants receive daily tVNS or sham sessions during 10 visits

2 weeks
10 visits (in-person)

Follow-up

Participants undergo two follow-up cognitive assessments to monitor changes in cognition and inflammatory responses

4 months
2 visits (in-person)

Treatment Details

Interventions

  • Active transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions
  • Sham transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions
Trial Overview The study examines if RAVANS (non-invasive electrical brain stimulation) can improve cognition in older adults. Participants will receive either the actual tVNS treatment or a sham (fake) version during ten-minute sessions to compare effects on brain function.
Participant Groups
6Treatment groups
Experimental Treatment
Placebo Group
Group I: cross-over Stimulation-ShamExperimental Treatment2 Interventions
Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham One time RAVANS versus one time Sham Two weeks wash-out
Group II: cross-over Sham-StimulationExperimental Treatment2 Interventions
Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) One time RAVANS versus one time Sham Two weeks wash-out
Group III: Stimulation preceded by cross-over Stimulation-ShamExperimental Treatment1 Intervention
Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by sham Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
Group IV: Stimulation preceded by cross-over Sham-StimulationExperimental Treatment1 Intervention
Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of RAVANS during 2 weeks
Group V: Sham preceded by cross-over Sham-StimulationPlacebo Group1 Intervention
Cross-over: Sham followed by experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Wash-out period of four weeks Ten daily sessions of sham during 2 weeks
Group VI: Sham preceded by cross-over Stimulation-ShamPlacebo Group1 Intervention
Cross-over: experimental Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) followed by Sham Wash-out period of four weeks Ten daily sessions of sham during 2 weeks

Find a Clinic Near You

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials
3,066
Recruited
13,430,000+

National Institute on Aging (NIA)

Collaborator

Trials
1,841
Recruited
28,150,000+

Findings from Research

A pilot study involving 24 patients with chronic tinnitus demonstrated that transcutaneous vagus nerve stimulation (tVNS) is a feasible and generally safe treatment method, with only two adverse cardiac events reported, which were unlikely linked to the device.
Preliminary data suggest that tVNS does not cause arrhythmic effects in patients without known heart conditions, indicating its potential safety for cardiac function.
Transcutaneous vagus nerve stimulation: retrospective assessment of cardiac safety in a pilot study.Kreuzer, PM., Landgrebe, M., Husser, O., et al.[2022]
Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive and cost-effective method for modulating the vagus nerve, making it a promising alternative to traditional surgical vagus nerve stimulation.
taVNS allows for easy and safe administration, with considerations for proper electrode placement and individual dosing based on perception thresholds, which enhances its potential for treating various central and peripheral diseases.
Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS): Technique, Targeting, and Considerations.Badran, BW., Yu, AB., Adair, D., et al.[2020]
In a study involving 15 patients with chronic pelvic pain due to endometriosis, respiratory-gated auricular vagal afferent nerve stimulation (RAVANS) showed a trend towards reducing pain intensity and significantly decreased anxiety compared to nonvagal auricular stimulation (NVAS).
RAVANS demonstrated moderate to large effect sizes in reducing pain and anxiety, suggesting it could be a promising nonpharmacological treatment option for chronic pain disorders, warranting further investigation into its long-term effects.
Evoked pain analgesia in chronic pelvic pain patients using respiratory-gated auricular vagal afferent nerve stimulation.Napadow, V., Edwards, RR., Cahalan, CM., et al.[2022]

References

Transcutaneous vagus nerve stimulation: retrospective assessment of cardiac safety in a pilot study. [2022]
Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS): Technique, Targeting, and Considerations. [2020]
Evoked pain analgesia in chronic pelvic pain patients using respiratory-gated auricular vagal afferent nerve stimulation. [2022]
Transcutaneous auricular vagus nerve stimulation therapy in patients with cognitively preserved structural focal epilepsy: A case series report. [2023]
[Clinical Application of Transcutaneous Auricular Vagus Nerve Stimulation]. [2022]
Safety of transcutaneous auricular vagus nerve stimulation (taVNS): a systematic review and meta-analysis. [2023]
Transcutaneous auricular vagus nerve stimulators: a review of past, present, and future devices. [2022]
Transcutaneous Auricular Vagus Nerve Stimulation Normalizes Induced Gastric Myoelectrical Dysrhythmias in Controls Assessed by Body-Surface Gastric Mapping. [2023]
Transcutaneous vagus nerve stimulation - A brief introduction and overview. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Neurophysiologic effects of transcutaneous auricular vagus nerve stimulation (taVNS) via electrical stimulation of the tragus: A concurrent taVNS/fMRI study and review. [2020]
11.United Statespubmed.ncbi.nlm.nih.gov
Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study. [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year. [2022]
"The Wandering Nerve Linking Heart and Mind" - The Complementary Role of Transcutaneous Vagus Nerve Stimulation in Modulating Neuro-Cardiovascular and Cognitive Performance. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security